Akki. Once again you miss my point...Pfizer is for Acromegaly......

Akki. Once again you miss my point...Pfizer is for Acromegaly... yes. A 5 patient Acromegaly is small but it does get Pfizer to look at Anp......


“Giants like Pfizer (PFE, -0.14%) have tried to become more entrepreneurial, and some behemoths have beefed up R&D. Yet rarely do they conduct early scientific research anymore. Increasingly, the big players leave that to startups, then later cut deals to acquire or license the drugs. “Biotech is becoming more important than ever to Big Pharma and becoming the fuel source for their drug pipelines,” says Nicholson, who once scouted for such acquisitions at Merck. Small companies received $5.6 billion in upfront licensing payments in 2014, double the prior year, according to the trade group BIO.

Small companies offer the classic high-risk, high-reward dichotomy: a lot of the former, and handsome payouts in the case of the latter. Tony Coles, who spent 22 years at Bristol-Myers Squibb (BMY, +0.76%) and Merck, walked away with $62 million after serving as CEO of Onyx Pharmaceuticals, which was acquired by Amgen (AMGN, +0.89%) in 2013 for $9.7 billion. (Coles has since launched another startup.) Former Amgen executive Terry Rosen started Flexus Biosciences and sold it 17 months later for $1.3 billion. (His share was undisclosed.)